ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Sees Significant Increase in Short Interest

Posted by ABMN Staff on Feb 13th, 2026

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 21,029 shares, a growth of 99.1% from the January 15th total of 10,560 shares. Based on an average trading volume of 18,168 shares, the short-interest ratio is currently 1.2 days. Currently, 7.0% of the shares of the stock are short sold. Currently, 7.0% of the shares of the stock are short sold. Based on an average trading volume of 18,168 shares, the short-interest ratio is currently 1.2 days.

ProShares UltraShort Nasdaq Biotechnology Trading Up 1.9%

NASDAQ:BIS opened at $8.91 on Friday. The stock has a 50-day moving average price of $9.16 and a 200 day moving average price of $11.44. ProShares UltraShort Nasdaq Biotechnology has a 12-month low of $8.37 and a 12-month high of $25.87.

ProShares UltraShort Nasdaq Biotechnology Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Wednesday, December 24th were issued a dividend of $0.1026 per share. This represents a $0.41 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date of this dividend was Wednesday, December 24th.

Hedge Funds Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Csenge Advisory Group bought a new stake in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,421 shares of the company’s stock, valued at approximately $163,000. Csenge Advisory Group owned approximately 6.54% of ProShares UltraShort Nasdaq Biotechnology as of its most recent filing with the Securities & Exchange Commission.

ProShares UltraShort Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.